• Biogen's collaboration with Eisai Co., Ltd. on Alzheimer's treatment "LEQEMBI" marks a significant stride in neurological disease management.
• The acceptance of the Biologics License Application for LEQEMBI in China could open new market opportunities for Biogen.
• Biogen's stock has seen a 15.1% increase in 2025, driven by successful product launches and a 29.9% increase in sales for Skyclarys.

Biogen Inc. (NASDAQ:BIIB) is a leading biotechnology company with a focus on developing treatments for neurological diseases. In collaboration with Eisai Co., Ltd., Biogen is advancing the development of treatments like "LEQEMBI" for Alzheimer's disease, positioning itself as a strong competitor against pharmaceutical giants like Eli Lilly.

UBS recently set a price target of $185 for Biogen, slightly above its current price of $182.61. This valuation reflects optimism about Biogen's strategic initiatives and its potential for growth, particularly in the Alzheimer's treatment market.

The recent acceptance of the Biologics License Application for LEQEMBI's subcutaneous formulation in China represents a significant milestone for Biogen. Approval in this market would mark the introduction of the first anti-amyloid treatment in China capable of at-home injections for early Alzheimer's disease, potentially broadening Biogen's market presence in Asia.

Despite some skepticism from retail investors, Biogen's stock has demonstrated resilience, with a 15.1% increase in 2025. This growth is attributed to the successful launch of LEQEMBI and the strong performance of Skyclarys, a treatment for Friedreich's ataxia, which saw a 29.9% increase in sales, reaching $132.9 million in the third quarter.

Currently, Biogen's stock is trading at $182.61, reflecting a 4.57% increase. The stock has experienced fluctuations between $174.30 and $182.97 today. Over the past year, it reached a high of $185.17 and a low of $110.04. Biogen's market capitalization stands at approximately $26.79 billion, with a trading volume of 2,115,043 shares.